JM

Cascade BioSciences Inc.

TSX: CSBX

Mid-cap oncology developer. Lead candidate CSB-204 in Phase II. Disclosure quality has deteriorated across the last two reporting cycles.

OverviewFlagsFilingsContradictionsRisksNetworkEnforcementInsider trades

Merevix milestone revenue: full recognition (FY23) vs. partial deferral (FY24 restatement)

Prior disclosure
Mar 30, 2024
“Revenue for the year was $18.0 million, including $4.0 million of milestone payments from Merevix recognized in full upon receipt during Q3 2023.”
↳ SP-2024-03-30-CSBX-MDA-11842
Current disclosure
Mar 28, 2025
“Comparative figures for the year ended December 31, 2023 have been restated to defer $2,100 of milestone revenue previously recognized in Q3 2023.”
↳ SP-2025-03-28-CSBX-AFS-12045
Analysis

The FY2024 financial statements quietly restate FY2023 milestone revenue, but the FY2024 MD&A cover narrative does not characterize the change as a restatement — it is presented as a 'deferral'. NI 51-102 contemplates explicit restatement disclosure.

BLA timeline shifted without acknowledgement

Prior disclosure
Mar 30, 2024
“The Company believes CSB-204 is positioned for a 2025 BLA submission with US commercial launch targeted for 2026.”
↳ SP-2024-03-30-CSBX-MDA-11842
Current disclosure
Mar 28, 2025
“Management anticipates that the CSB-204 Phase II readout will support a 2026 BLA submission and US commercial launch in 2027.”
↳ SP-2025-03-28-CSBX-MDA-12044